25Jul

EKF POC HbA1c analyzer demonstrates excellent performance in international evaluation study

EKF_1

Cardiff, UK – 19 July 2018 – EKF Diagnostics, the global in vitro diagnostics company, has announced the successful evaluation of its Quo-Lab® point-of-care HbA1c analyzer by the European Reference Laboratory for Glycohemoglobin. In a recently published paper [1], the reference laboratory’s evaluation study assessed HbA1c (glycated hemoglobin) POC devices using international quality targets, posing the question ‘Are they fit for purpose?’ Out of 30 available on the market and the four that agreed to participate, only EKF’s Quo-Lab and one other analyzer passed the same stringent quality criteria as laboratory analyzers, achieving excellent analytical performance.

The study aimed to evaluate the four POC HbA1c instruments according to Clinical and Laboratory Standards Institute (CLSI) protocols and how they performed when different criteria were applied using four certified IFCC and NGSP secondary reference measurement procedures (SRMPs). The reference laboratory study confirmed there was minimal bias between Quo-Lab and the mean of four SRMPs, it also passed all relevant performance criteria going far beyond what is required for NGSP and IFCC certification.

Notably, Quo-Lab showed no consistent clinically significant interference from the common hemoglobin (Hb) variants HbAS, HbAC, HbAD, HBAE and elevated A2. It also easily met imprecision criteria, achieving a ≤2.4% CV in IFCC SI units and ≤1.7% CV in DCCT units which represents a significant improvement on previous studies.

This evaluation success follows last year’s similarly excellent evaluation of EKF’s Quo-Test® HbA1c analyzer which was again confirmed to meet IFCC performance criteria [2]. Although not included in this latest study, Lenters-Westra felt it important enough to mention in the conclusion that the Quo-Test’s improved performance also had no bias compared to the mean of three SRMPs [1].

Commenting on the successful European Reference Laboratory for Glycohemoglobin evaluation, Gavin Jones, Diabetes Product Manager, EKF Diagnostics said, “The excellent performance that Quo-Lab has demonstrated in this latest study confirms that it is very definitely fit for purpose, delivering reliable HbA1c results in a range of settings. This study also highlights the performance improvements that we have made to both our Quo-Lab and Quo-Test HbA1c analyzers to fulfill increasingly tough requirements from the IFCC. This means that both analyzers meet the same rigorous quality criteria as laboratory analyzers.”

Quo-Lab® HbA1c is a desktop analyzer designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand low cost of operation and ease of use. From a simple semi-automated procedure, Quo-Lab provides test results within four minutes from a venous or finger prick blood sample of just 4 μL. Quo-Lab uses the same boronate affinity methodology as Quo-Test which is also unaffected by Hb variants. Step-by-step instructions are displayed on a clear, multi-lingual display, therefore, staff training time is minimized and opportunity for error reduced. Quo-Lab is CE marked and available for sale in most global markets subject to local registration requirements.

For full information on the EKF Diagnostics Group, please visit www.ekfdiagnostics.com

References:

  1. Lenters-Westra, E. & English, E. Evaluation of four HbA1c point-of-care devices using international quality targets: Are they fit for purpose? J Diabetes Sci Technol. 2018 Jul;12(4):762-770. 
  2. Lenters-Westra, E. & English, E. Understanding the use of sigma metrics in hemoglobin A1c analysis. Clin Lab Med 2017;37: 57-71.

Related

MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated I...

Read More >

OGT continues move into molecular diagnostics markets with MDSAP certification

Certification of new Cambridge facility smooths path to future IVD approvals

Read More >

First multi-site installation of HORIBA Medical’s new HELO modular automated haematology platform

Northampton, UK – 28th May 2019 – HORIBA UK Ltd, Medical announces the go live of the first multi-...

Read More >

EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

FDA cleared POC hemoglobin analyzer to be sold across the USA by the market’s leading and most esta...

Read More >

Cytox awarded new Innovate UK funding for Alzheimer’s disease testing

8 March 2018: Oxford & Manchester, UK. Cytox, an emerging precision medicine leader providing geneti...

Read More >

Improved Nucleic Acid Isolation

New QuickGene Range for DNA & RNA Extraction- Now with Automated Option

Read More >